Overview
- 6 public-safe observations are available for this inspection.
- 6 structured CFR citations are represented.
- 1 investigator is tied to this Form 483.
Inspectional observations
Each observation cites the regulation FDA found the firm out of compliance with.
29 Jul 2022
21 CFR 111.113(b)(2)
Quality control - reject; specification not met
Cited by Denise Connelly
29 Jul 2022
21 CFR 111.205(a)
Master manufacturing record - unique formulation
Cited by Denise Connelly
29 Jul 2022
21 CFR 111.70(e)
Specifications - identity, purity, strength, composition
Cited by Denise Connelly
29 Jul 2022
21 CFR 111.75(a)(2)
Component - confirm identity; specifications met
Cited by Denise Connelly
Inspected site
OPOHM Pharma, Inc.Mineral Wells, United States
Inspection team
Cited regulations
CFR citations associated with this Form 483.
| Citation | What it covers | Cited |
|---|---|---|
| 21 CFR 111.113(b)(2) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 111.15(i) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 111.205(a) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 111.70(e) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 111.75(a)(2) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 111.75(h)(2) | Cited across public-safe Form 483 observations | 1x |
Source document
PDF
PDF available
Form 483 source document
The source document is available to authorized Atlas users.
Full 483 report
Get the verbatim text of all 6 observations
The source PDF, so your team sees exactly what was cited and how it was answered.
- The site's full inspection history around this Form 483
- Whether these citations escalated to a warning letter
- The investigators involved and the citations they repeat elsewhere